nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylnaltrexone—Stinging—Mometasone—systemic scleroderma	0.0505	0.0505	CcSEcCtD
Methylnaltrexone—Injection site reaction—Mycophenolate mofetil—systemic scleroderma	0.0222	0.0222	CcSEcCtD
Methylnaltrexone—Erythema—Pentoxifylline—systemic scleroderma	0.0207	0.0207	CcSEcCtD
Methylnaltrexone—Flatulence—Pentoxifylline—systemic scleroderma	0.0204	0.0204	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Pentoxifylline—systemic scleroderma	0.0175	0.0175	CcSEcCtD
Methylnaltrexone—Oedema—Pentoxifylline—systemic scleroderma	0.0169	0.0169	CcSEcCtD
Methylnaltrexone—Skin disorder—Pentoxifylline—systemic scleroderma	0.0164	0.0164	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Pentoxifylline—systemic scleroderma	0.0163	0.0163	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Pentoxifylline—systemic scleroderma	0.0138	0.0138	CcSEcCtD
Methylnaltrexone—Abdominal pain—Pentoxifylline—systemic scleroderma	0.0134	0.0134	CcSEcCtD
Methylnaltrexone—Flatulence—Leflunomide—systemic scleroderma	0.0128	0.0128	CcSEcCtD
Methylnaltrexone—Pain—Mometasone—systemic scleroderma	0.0125	0.0125	CcSEcCtD
Methylnaltrexone—Flatulence—Mycophenolic acid—systemic scleroderma	0.0122	0.0122	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Mometasone—systemic scleroderma	0.0119	0.0119	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—systemic scleroderma	0.0116	0.0116	CcSEcCtD
Methylnaltrexone—Diarrhoea—Pentoxifylline—systemic scleroderma	0.0116	0.0116	CcSEcCtD
Methylnaltrexone—Abdominal pain—Mometasone—systemic scleroderma	0.0115	0.0115	CcSEcCtD
Methylnaltrexone—Dizziness—Pentoxifylline—systemic scleroderma	0.0112	0.0112	CcSEcCtD
Methylnaltrexone—Erythema—Lisinopril—systemic scleroderma	0.0111	0.0111	CcSEcCtD
Methylnaltrexone—Flatulence—Lisinopril—systemic scleroderma	0.011	0.011	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Leflunomide—systemic scleroderma	0.0109	0.0109	CcSEcCtD
Methylnaltrexone—Skin disorder—Azathioprine—systemic scleroderma	0.0109	0.0109	CcSEcCtD
Methylnaltrexone—Vomiting—Pentoxifylline—systemic scleroderma	0.0108	0.0108	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Captopril—systemic scleroderma	0.0105	0.0105	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—systemic scleroderma	0.0104	0.0104	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Leflunomide—systemic scleroderma	0.0104	0.0104	CcSEcCtD
Methylnaltrexone—Skin disorder—Leflunomide—systemic scleroderma	0.0103	0.0103	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Leflunomide—systemic scleroderma	0.0102	0.0102	CcSEcCtD
Methylnaltrexone—Abdominal pain—Captopril—systemic scleroderma	0.0101	0.0101	CcSEcCtD
Methylnaltrexone—Oedema—Mycophenolic acid—systemic scleroderma	0.0101	0.0101	CcSEcCtD
Methylnaltrexone—Nausea—Pentoxifylline—systemic scleroderma	0.01	0.01	CcSEcCtD
Methylnaltrexone—Diarrhoea—Mometasone—systemic scleroderma	0.00998	0.00998	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Mycophenolic acid—systemic scleroderma	0.00988	0.00988	CcSEcCtD
Methylnaltrexone—Skin disorder—Mycophenolic acid—systemic scleroderma	0.00979	0.00979	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Mycophenolic acid—systemic scleroderma	0.00974	0.00974	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.00966	0.00966	CcSEcCtD
Methylnaltrexone—Flatulence—Mycophenolate mofetil—systemic scleroderma	0.0096	0.0096	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.0094	0.0094	CcSEcCtD
Methylnaltrexone—Vomiting—Mometasone—systemic scleroderma	0.00928	0.00928	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.00915	0.00915	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.00912	0.00912	CcSEcCtD
Methylnaltrexone—Oedema—Lisinopril—systemic scleroderma	0.00908	0.00908	CcSEcCtD
Methylnaltrexone—Pain—Leflunomide—systemic scleroderma	0.00903	0.00903	CcSEcCtD
Methylnaltrexone—Abdominal pain—Azathioprine—systemic scleroderma	0.00884	0.00884	CcSEcCtD
Methylnaltrexone—Skin disorder—Lisinopril—systemic scleroderma	0.00882	0.00882	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Lisinopril—systemic scleroderma	0.00877	0.00877	CcSEcCtD
Methylnaltrexone—Diarrhoea—Captopril—systemic scleroderma	0.00877	0.00877	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.0087	0.0087	CcSEcCtD
Methylnaltrexone—Nausea—Mometasone—systemic scleroderma	0.00867	0.00867	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.00864	0.00864	CcSEcCtD
Methylnaltrexone—Pain—Mycophenolic acid—systemic scleroderma	0.00862	0.00862	CcSEcCtD
Methylnaltrexone—Dizziness—Captopril—systemic scleroderma	0.00848	0.00848	CcSEcCtD
Methylnaltrexone—Abdominal pain—Leflunomide—systemic scleroderma	0.00835	0.00835	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.00824	0.00824	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.00824	0.00824	CcSEcCtD
Methylnaltrexone—Vomiting—Captopril—systemic scleroderma	0.00815	0.00815	CcSEcCtD
Methylnaltrexone—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.00797	0.00797	CcSEcCtD
Methylnaltrexone—Oedema—Mycophenolate mofetil—systemic scleroderma	0.00795	0.00795	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.00784	0.00784	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.0078	0.0078	CcSEcCtD
Methylnaltrexone—Pain—Lisinopril—systemic scleroderma	0.00776	0.00776	CcSEcCtD
Methylnaltrexone—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.00772	0.00772	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.00769	0.00769	CcSEcCtD
Methylnaltrexone—Diarrhoea—Azathioprine—systemic scleroderma	0.00765	0.00765	CcSEcCtD
Methylnaltrexone—Nausea—Captopril—systemic scleroderma	0.00761	0.00761	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.00742	0.00742	CcSEcCtD
Methylnaltrexone—Dizziness—Azathioprine—systemic scleroderma	0.0074	0.0074	CcSEcCtD
Methylnaltrexone—Diarrhoea—Leflunomide—systemic scleroderma	0.00723	0.00723	CcSEcCtD
Methylnaltrexone—Abdominal pain—Lisinopril—systemic scleroderma	0.00718	0.00718	CcSEcCtD
Methylnaltrexone—Vomiting—Azathioprine—systemic scleroderma	0.00711	0.00711	CcSEcCtD
Methylnaltrexone—Dizziness—Leflunomide—systemic scleroderma	0.00699	0.00699	CcSEcCtD
Methylnaltrexone—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.00689	0.00689	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.00687	0.00687	CcSEcCtD
Methylnaltrexone—Pain—Mycophenolate mofetil—systemic scleroderma	0.0068	0.0068	CcSEcCtD
Methylnaltrexone—Vomiting—Leflunomide—systemic scleroderma	0.00672	0.00672	CcSEcCtD
Methylnaltrexone—Dizziness—Mycophenolic acid—systemic scleroderma	0.00666	0.00666	CcSEcCtD
Methylnaltrexone—Nausea—Azathioprine—systemic scleroderma	0.00664	0.00664	CcSEcCtD
Methylnaltrexone—Erythema—Prednisone—systemic scleroderma	0.0066	0.0066	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.0065	0.0065	CcSEcCtD
Methylnaltrexone—Vomiting—Mycophenolic acid—systemic scleroderma	0.00641	0.00641	CcSEcCtD
Methylnaltrexone—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.00629	0.00629	CcSEcCtD
Methylnaltrexone—Nausea—Leflunomide—systemic scleroderma	0.00627	0.00627	CcSEcCtD
Methylnaltrexone—Diarrhoea—Lisinopril—systemic scleroderma	0.00621	0.00621	CcSEcCtD
Methylnaltrexone—Dizziness—Lisinopril—systemic scleroderma	0.006	0.006	CcSEcCtD
Methylnaltrexone—Nausea—Mycophenolic acid—systemic scleroderma	0.00599	0.00599	CcSEcCtD
Methylnaltrexone—Vomiting—Lisinopril—systemic scleroderma	0.00577	0.00577	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.00558	0.00558	CcSEcCtD
Methylnaltrexone—Erythema—Methotrexate—systemic scleroderma	0.00552	0.00552	CcSEcCtD
Methylnaltrexone—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.00544	0.00544	CcSEcCtD
Methylnaltrexone—Nausea—Lisinopril—systemic scleroderma	0.00539	0.00539	CcSEcCtD
Methylnaltrexone—Oedema—Prednisone—systemic scleroderma	0.00539	0.00539	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Prednisone—systemic scleroderma	0.00529	0.00529	CcSEcCtD
Methylnaltrexone—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.00526	0.00526	CcSEcCtD
Methylnaltrexone—Skin disorder—Prednisone—systemic scleroderma	0.00524	0.00524	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Prednisone—systemic scleroderma	0.00521	0.00521	CcSEcCtD
Methylnaltrexone—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.00506	0.00506	CcSEcCtD
Methylnaltrexone—Nausea—Mycophenolate mofetil—systemic scleroderma	0.00472	0.00472	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.00467	0.00467	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Methotrexate—systemic scleroderma	0.00442	0.00442	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Prednisone—systemic scleroderma	0.00441	0.00441	CcSEcCtD
Methylnaltrexone—Skin disorder—Methotrexate—systemic scleroderma	0.00438	0.00438	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Methotrexate—systemic scleroderma	0.00436	0.00436	CcSEcCtD
Methylnaltrexone—Abdominal pain—Prednisone—systemic scleroderma	0.00426	0.00426	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.00389	0.00389	CcSEcCtD
Methylnaltrexone—Pain—Methotrexate—systemic scleroderma	0.00385	0.00385	CcSEcCtD
Methylnaltrexone—Diarrhoea—Prednisone—systemic scleroderma	0.00369	0.00369	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.00368	0.00368	CcSEcCtD
Methylnaltrexone—Dizziness—Prednisone—systemic scleroderma	0.00356	0.00356	CcSEcCtD
Methylnaltrexone—Abdominal pain—Methotrexate—systemic scleroderma	0.00356	0.00356	CcSEcCtD
Methylnaltrexone—Vomiting—Prednisone—systemic scleroderma	0.00343	0.00343	CcSEcCtD
Methylnaltrexone—Nausea—Prednisone—systemic scleroderma	0.0032	0.0032	CcSEcCtD
Methylnaltrexone—Diarrhoea—Methotrexate—systemic scleroderma	0.00308	0.00308	CcSEcCtD
Methylnaltrexone—Dizziness—Methotrexate—systemic scleroderma	0.00298	0.00298	CcSEcCtD
Methylnaltrexone—Vomiting—Methotrexate—systemic scleroderma	0.00286	0.00286	CcSEcCtD
Methylnaltrexone—Nausea—Methotrexate—systemic scleroderma	0.00268	0.00268	CcSEcCtD
